The role of glucagon/PKA inducible coactivator peroxisome proliferator activated receptor γ coactivator-1 α (PGC-1α) signaling pathway is well-characterized in hepatic gluconeogenesis. However, an opposing PKB/Akt inducible corepressor signaling pathway is unknown. A previous report has demonstrated that Small heterodimer partner interacting leucine zipper protein (SMILE) regulates the nuclear receptors and transcriptional factors that control hepatic gluconeogenesis. Here, we show that hepatic SMILE expression was induced by feeding in normal mice, but not in db/db and high fat diet-fed (HFD) mice. Interestingly, SMILE expression was induced by insulin in mouse primary hepatocyte and liver. Hepatic SMILE expression was not altered by refeeding in liver specific insulin receptor knockout (LIRKO) or protein kinase B beta-deficient (PKBβ -/-) mice. At the molecular level, SMILE inhibited HNF4-mediated transcriptional activity via direct competition with PGC-1α. Moreover, ablation of SMILE augmented gluconeogenesis and increased blood glucose levels in mice. Conversely, overexpression of SMILE reduced hepatic gluconeogenic genes expression and ameliorated hyperglycemia and glucose intolerance in db/db and high fat diet-fed mice. Therefore, SMILE is an insulin-inducible corepressor that suppresses hepatic gluconeogenesis. Small molecules that enhance SMILE expression would have potential for treating hyperglycemia in diabetes.
INTRODUCTION
Insulin induces the insulin receptor tyrosine kinase-mediated activation of the phosphatidylinositol 3-kinase (PI3K) pathway that controls hepatic glucose production.
Ablation of insulin signalling leads to the increased gluconeogenesis in type 2 diabetes (1-3). In the fed condition, insulin inhibits hepatic gluconeogenesis by down regulating the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). This pathway involves phosphorylation of the forkhead transcription factor FOXO1 and CBP (4-7) and recruitment of coactivators, including peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α) and CREBregulated transcription co-activator 2 (CRTC2) (8, 9) .
Small heterodimer partner interacting leucine zipper protein (SMILE), including two alternative translation-derived isoforms, SMILE-L (CREBZF; long form of SMILE) and SMILE-S (Zhangfei; short form of SMILE), has been classified as a member of the CREB/ATF family of basic region-leucine zipper (bZIP) transcription factors. However, SMILE cannot bind to DNA as a homodimer (10, 11, 12) . SMILE has also been reported to function as a coactivator of ATF4 or as a corepressor of HCFbinding transcription factor (13, 14) . Previously, we have reported that SMILE is a corepressor of the estrogen receptor-related receptor gamma (ERRgamma), glucocorticoid receptor (GR), constitutive androstane receptor (CAR), hepatocyte nuclear factor 4α (HNF4α), and cAMP responsive element-binding protein H (CREBH) (15, 16, 17) . A recent study demonstrated that SMILE activates tumor suppressor p53 and inhibits the function of BMP-6 by interacting with Smads (18, 19) . However, the roles of SMILE in hepatic glucose metabolism still need to be clarified.
PGC-1α is a multifunctional transcriptional coactivator involved in diverse
Page 3 of 39 Diabetes physiological metabolisms. In the liver, PGC-1α expression is induced in the fasting state and increases the expression of gluconeogenic genes via direct interaction with transcription factors including HNF4α, FOXO1, and GR (8, 20) . Overexpression of PGC-1α leads to the increased expression of G6Pase and PEPCK, key enzymes in the hepatic glucose production. Conversely, knockdown or knockout of PGC-1α results in the lower blood glucose levels as a result of reduced gluconeogenesis.
In this report, we show that SMILE is tightly regulated by the nutritional status, displaying an opposite expression pattern compared to PGC-1α. Whereas hepatic SMILE expression was elevated in the fed state relative to fasting, this regulation was lost in the absence of insulin signaling. Moreover, SMILE regulates hepatic gluconeogenesis via inhibition of PGC-1α-mediated gluconeogenic genes expression.
Collectively, this study indicates that SMILE counteracts the stimulatory effect of PGC-1α on hepatic gluconeogenesis and plays important role for insulin action on hepatic glucose metabolism.
RESEARCH DESIGN AND METHODS

Animal experiments
Four-weeks-old male C57BL/6 mice (for the DIO model) purchased from Orient Basel, Switzerland) as described previously (21) . Adenoviruses GFP and SMILE were To measure fasting blood glucose levels, animals were fasted for 4 h with free access to water. To activate the insulin signaling pathway, either PBS (for control) or insulin (0.5 unit/kg body wt) was injected intraperitoneally for 1-12 h before the collection of liver for further analyses. All procedures were performed in a specific pathogen-free facility at the Korea University College of Medicine (Seoul, Korea), based on the protocols that were approved by the Korea University Institutional Animal Care & Use Committee.
Glucose, insulin and pyruvate tolerance test
For the glucose or pyruvate tolerance tests, mice were fasted for 16 h and then injected intraperitoneally with 2 g/kg glucose or 1-1.5 g/kg pyruvate (on day 6 post-adenoviral injection). Plasma glucose levels were measured using blood drawn from the tail vein at designated time points using an automatic glucose monitor (One Touch, LifeScan Ltd., Milpitas, CA USA). For the insulin tolerance test, mice were fasted for 4 h and then injected intraperitoneally with 0.75-1 unit/kg of insulin on day 6 after adenoviral injection.
Insulin measurement
Plasma insulin was measured using plasma collected at time of sacrifice by using mouse insulin ELISA kit (Shibayagi Co., Ltd., Ishihara Japan).
Glycogen assay
Liver tissue 30mg are homogenized in ice cold 0.1M Citrate buffer(pH 4.2)+NaF and glycogen were measured using Enzychrom Glycogen assay kit ((Bioassay Systems, Hayward, CA, USA), according to the manufacturer's instructions.
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Glucose output assay
Glucose production from primary hepatocytes was measured according to the manufacturer's protocol, using a colorimetric glucose oxidase assay (Sigma). Primary hepatocytes were seeded, cultured for 24 h, the cells were washed three times with phosphate-buffered saline and the medium was then replaced with glucose production buffer (glucose-free DMEM, pH 7.4, containing 20 mmol/liter sodium lactate, 1 mmol/liter sodium pyruvate, and 15 mmol/liter HEPES, without phenol red). The glucose assays were performed in triplicate.
Chemicals
Insulin was purchased from Sigma Aldrich (St. Louis, MO, USA). Forskolin (FSK) was purchased from Calbiochem and dissolved in the recommended solvents. and CMV-β-galactosidase plasmids were cotransfected as an internal control. The cells were harvested 48 h after the transfection, and luciferase activity was measured and normalized to β-galactosidase activity.
Cell culture and transient transfection assay
Culture of primary hepatocytes
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Primary hepatocytes were prepared from C57BL/6 mice by the collagenase perfusion method as described previously (22) . After attachment, cells were infected with adenoviruses for 18 h. Subsequently, cells were maintained in the serum-free Medium 199 media (Mediatech) for overnight and treated with 10 µM forskolin and/or 100 nM insulin.
Recombinant adenovirus
Adenoviruses expressing unspecific shRNA, shSMILE, control GFP, SMILE, HNF4α, PGC-1α, SREBP-1c and dn-SREBP-1c were described previously (17, 22, 23, 24) . All viruses were purified by using CsCl 2 or the Adeno-X Maxi Purification Kit (Clontech, Mountain View, CA USA).
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed as described previously (17) . In brief, mouse livers (40 mg/sample) were fixed with 1% formaldehyde and sonicated. The soluble chromatin was then subjected to immunoprecipitation using anti-HA (#2367, Cell Signaling Technology), anti-FLAG (#2368, Cell Signaling Technology), anti-PGC-1α (sc-13067, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-SMILE (sc-49329, Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by treatment with Protein Aagarose/salmon sperm DNA (Upstate Biotechnology, Upstate, NY, USA). DNA samples were quantified by quantitative real time PCR using two pairs primers of the mouse Pepck promoter follows: forward (5'-GATGTAGACTCTGTCCTG-3') and reverse (5'-GATTGCTCTGCTATGAGT-3') or mouse G6Pase promoter follows:
forward (5'-CCTTGCCCCTGTTTTATATGCC-3') and reverse (5'-CGTAAATCACCC TGAACATGTTTG-3') or mouse PGC-1α promoter follows: forward (5'-GCCTATGA GCACGAAAGGCT-3') and reverse (5'-GCGCTCTTCAATTGCTTTCT-3').
Western blot analysis
Whole-cell extracts were prepared using RIPA buffer (Elpis-Biotech, Korea). Proteins from whole-cell lysates were separated by 10% SDS-PAGE, and then transferred to nitrocellulose membranes. The membranes were probed with indicated antibodies.
Immunoreactive proteins were visualized using an ECL kit Amersham ECL kit (GE Healthcare, Piscataway, NJ, USA), according to the manufacturer's instructions.
Quantitative PCR
Total RNA from primary hepatocytes or liver was extracted using an RNeasy mini-kit (Qiagen). All of the samples were combined for the experiment. cDNA was generated by Superscript II enzyme (Invitrogen) and analyzed by Q-PCR using a SYBR green PCR kit and an TP800 Thermal Cycler DICE Real Time system (Takara). All data were normalized to ribosomal L32 expression.
Statistical analyses
All values are expressed as means ± S.E.M. The significance between mean values was evaluated by a two-tailed unpaired Student's t-test.
RESULTS
Hepatic SMILE gene expression is elevated by refeeding in normal mice, but not in insulin-resistant mice. To investigate whether SMILE plays a role in glucose homeostasis, we monitored the effect of different nutritional conditions on hepatic SMILE gene expression in mouse liver. Ad libitum feeding increased SMILE expression in liver compared with 6 h fasted mice (Fig. 1A) . To further confirm the induction of
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SMILE expression in the refed condition, protein levels of SMILE were measured in the liver from fasted and refed mice. As expected, hepatic SMILE protein levels were increased by refeeding in a time dependent manner while PGC-1α protein levels were decreased (Fig. 1B) . These results indicated that SMILE expression may be elevated by a signal induced by feeding. On the basis of SMILE gene expression in different nutritional conditions, we investigated whether insulin signaling is responsible for the modulation of hepatic SMILE gene expression in vivo. To confirm this, we examined whether SMILE expression is also increased by refeeding in insulin resistant mouse models. qPCR analysis showed that the expression of hepatic SMILE was significantly higher in the refed conditions in normal mice but not in db/db mice (Fig. 1C) . A similar pattern of SMILE protein levels was observed in response to fasting and refeeding conditions in normal versus db/db mice (Fig. 1D) . Furthermore, SMILE mRNA ( insulin resistant mouse models, insulin signaling would be expected to modulate hepatic SMILE gene expression in vivo. To examine this hypothesis, we injected wild type mice with insulin and measured hepatic SMILE gene expression levels. As expected, insulin injection led to a significant induction of hepatic SMILE mRNA and protein in wild type mice ( Fig. 2A and B) . Therefore, we hypothesized that if insulin activates SMILE gene expression during refeeding condition, then liver specific insulin receptor knockout promoter activity in a dose dependent manner (Fig. 3A) . We also found that insulin triggered induction of SMILE levels in a time dependent manner (Fig. 3B) . Consistent with the increased SMILE mRNA expression, exposure of mouse primary hepatocytes to insulin also increased the protein levels of SMILE in a time dependent manner (Fig.   3C ). Based on the ability of insulin to enhance the hepatic SMILE gene expression, we
Page 10 of 39 Diabetes examined whether PKB increases SMILE gene expression using constitutively active form of PKB (PKBca) adenovirus. Adenoviral overexpression of constitutively active PKB strongly increased SMILE mRNA and protein levels ( Fig. 3D and E) . Because insulin-induced protein modification such as phosphorylation often changes proteins amounts by triggering their nuclear export (5-8), we examined the effects of insulin on subcellular localization of SMILE. Insulin treatment triggered increased accumulation of SMILE in the nucleus in a time dependent manner, whereas the amounts of SMILE in the cytoplasm were not altered (Fig. 3F) . Interestingly, forskolin treatment decreased the basal and insulin-stimulated SMILE gene expression ( Fig. 1A ). Moreover, insulin-induced SMILE expression was blocked by overexpression of dominant negative SREBP-1c (dnSREBP-1c) (Supplementary Fig.   1B ). Collectively, these results indicated that insulin/PKB signal pathway increases hepatic SMILE gene expression at the transcriptional level rather than at the level of protein modification.
SMILE decreases HNF4α-induced gluconeogenic gene expression via competing
with PGC-1α. PGC-1α is induced by cAMP/PKA signaling in hepatocytes and is strongly increased in the liver by fasting (25) . Here, we found that hepatic PGC-1α was expressed in an opposite pattern to SMILE and was significantly elevated in both LIRKO and PKBβ -/-mice. Having seen the opposite expression pattern between SMILE
and PGC-1α, we then examined the effect of SMILE on PGC-1α transcriptional activity.
SMILE inhibited PGC-1α-mediated G6Pase, and Pepck promoter activity (Fig. 4A ).
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Moreover, PGC-1α-mediated G6Pase and Pepck expression and hepatic glucose production were significantly decreased by SMILE ( Fig. 4B and C) . A previous report demonstrated that PGC-1α activates G6Pase and Pepck gene expression by functional interaction with hepatic nuclear factor 4alpha (HNF4α) (8) . We have also reported that SMILE interacts with HNF4α and inhibits transcriptional activity of the HNF4α (16).
To explore whether PGC-1α-induced HNF4α transcriptional activity is repressed by SMILE, AML-12 cells were co-transfected with HNF4α, PGC-1α and SMILE expression vector together with gluconeogenic genes promoter-reporter constructs.
HNF4α-mediated induction of G6Pase and PEPCK promoter activity was significantly decreased by SMILE but was recovered by coexpression of PGC-1α (Fig. 4D) .
Next, to examine whether SMILE can affect the PGC-1α occupancy on the HNF4α binding region of the G6Pase and Pepck promoter in different nutritional conditions, we performed ChIP assays using fasted or refed mouse liver tissues. We observed increased occupancy of PGC-1α in the HNF4α binding region of the G6Pase
and Pepck promoter in the fasted condition compared to the refed condition, whereas the occupancy of SMILE was significantly increased in the refed condition, which is completely opposite to the occupancy of PGC-1α (Fig. 4E) . Moreover, overexpression of SMILE significantly decreased PGC-1α occupancy in the HNF4α binding region of the G6Pase and Pepck promoter. In contrast, overexpression of PGC-1α decreased SMILE occupancy in the HNF4α binding region (Fig. 4F) . These results suggest that SMILE competes with PGC-1α in forming a complex with HNF4α on G6Pase and Pepck promoter. Moreover, adenoviral overexpression of SMILE markedly inhibited HNF4α-mediated G6Pase, and Pepck gene expression (Fig. 4G ) or hepatic glucose production (Fig. 4H) . We have also assessed the effect of SMILE on glycolytic gene Fig. 2A and B) . These results indicate that SMILE specifically affects gluconeogenesis in the liver. A previous report showed that activation of FOXO1 by PGC-1a is required for gluconeogenic genes expression (20) .
We found that SMILE inhibits FOXO1-mediated hepatic gluconeogenic genes promoter activity or expression. Moreover, SMILE directly interacts with FOXO1 and competes with PGC-1α to inhibit FOXO1 transcriptional activity ( Supplementary Fig. 3A-D) .
Taken together, these results demonstrate that SMILE regulates the HNF4α-mediated PEPCK and G6Pase gene expression via competing with PGC-1α and stimulatory effect of PGC-1α on FOXO1 is also inhibited by SMILE.
Knockdown of SMILE gene expression causes hyperglycemia in mice.
The action of insulin in suppression of gluconeogenesis occurs rapidly via phosphorylation or dephosphorylation of its target molecules, whereas SMILE is regulated by insulin through gene transcription level. We assessed the effect of insulin-mediated SMILE gene expression on hepatic gluconeogenesis in early or delayed response to insulin. In the early response to insulin, knockdown of SMILE did not show any significant effect on insulin-mediated repression, whereas insulin-mediated repression of hepatic glucose output (Fig. 5A ) and gluconeogenic gene expression (Fig. 5B) were significantly relieved by knockdown of SMILE in the delayed time. These results indicate that prolonged inhibition of hepatic gluconeogenesis by insulin occurs via induction of SMILE expression in the later time point. Next, we hypothesized that alteration in SMILE gene expression would affect hepatic glucose metabolism in vivo. To explore the action of hepatic SMILE in vivo, we injected mice with an adenovirus expressing shRNA against SMILE. As expected, knockdown of endogenous SMILE in the liver elicited a marked increase of fasting blood glucose levels in mice (Fig. 5C) . However, plasma insulin levels were unaltered in Ad-shSMILE injected mice compared with Ad-US injected mice (Fig. 5D) . Moreover, we confirmed a marked induction of hepatic gluconeogenic gene expression such as Pepck and G6Pase upon SMILE knockdown (Fig. 5E) . Next, we further investigated whether ablation of endogenous SMILE affect glucose excursion, insulin sensitivity, and hepatic glucose production. During an intraperitoneal glucose tolerance test (GTT), glucose tolerance was significantly attenuated in Ad-shSMILE injected mice compared with control mice (Fig. 5F ).
However, ablation of endogenous SMILE did not lead to the significant changes in insulin sensitivity as observed by insulin tolerance test (ITT) in vivo (Fig. 5G) . To examine the impact of ablation of endogenous SMILE on hepatic glucose production, we also performed a pyruvate tolerance test (PTT). Ablation of endogenous SMILE elevated the pyruvate-dependent increase of blood glucose levels (Fig. 5H) .
Overexpression of SMILE in normal mice improves glucose tolerance without markedly affecting fasting blood glucose level. Based on the fact that ablation of SMILE increases blood glucose levels or hepatic gluconeogenesis, we suspected that induction of SMILE would have effects on hepatic glucose metabolism in normal mice.
Adenovirus-mediated expression of SMILE did not elicit a significant change in overnight fasting blood glucose levels or liver glycogen contents (Fig. 6A and B) . On the contrary, overexpression of SMILE significantly improved glucose tolerance and reduced gluconeogenesis as shown by improved pyruvate tolerance and reduced gluconeogenic gene expression (Fig. 6C-E) . In addition, overexpression of SMILE did Page 14 of 39 Diabetes not cause significant induction of insulin signaling in the liver or in the muscle of normal chow-fed mice ( Supplementary Fig. 4A and B) . These results indicate that SMILE significantly improved glucose tolerance or pyruvate tolerance without affecting glycogen levels in normal chow diet fed-mice.
SMILE decreases gluconeogenic gene expression and improves hyperglycemia in diabetic mice models. We next hypothesized that alteration in SMILE expression
would affect hepatic glucose metabolism in diabetic mice. To further assess the functional consequences of SMILE-mediated repression in gluconeogenic gene expression and improvement of blood glucose level, we performed adenoviral overexpression of SMILE in db/db and high fat diet (HFD) mice. The adenovirus GFP (Ad-GFP) and SMILE (Ad-SMILE) injected mice showed similar body weights (Fig.   7A ), but overexpression of SMILE significantly reduced fasting blood glucose levels in db/db and HFD mice (Fig. 7B) . Moreover, we observed a significant improvement of glucose tolerance and pyruvate tolerance without affecting insulin sensitivity in Ad-SMILE injected db/db or HFD mice compared with Ad-GFP injected db/db or HFD mice ( Fig. 7C-E) . Concomitantly, there was a significant reduction in mRNA levels of hepatic gluconeogenic gene, such as G6Pase, Pepck and Pgc-1α in Ad-SMILE injected db/db or HFD mice compared with Ad-GFP injected db/db or HFD mice (Fig. 7F and   G) . However, overexpression of SMILE did not lead to significant enhanced insulin signaling either in the liver or in the muscle of HFD mice ( Supplementary Fig. 4C and   D ). Taken together, these results suggest that SMILE directly regulate hepatic glucose metabolism in diabetic mice. Therefore, activation of SMILE could be a new therapeutic approach to treat diabetes by suppressing gluconeogenesis and ameliorating hyperglycemia.
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DISCUSSION
Insulin is the major hormone for the regulation of hepatic glucose metabolism by suppressing the expression of gluconeogenic enzyme genes (7, 9, 20) . SMILE expression was increased by refeeding condition, but not in fasting condition or insulin resistant status such as HFD and db/db mice. Thus, it seemed that the insulin/PKB pathway plays a major role in the regulation of SMILE expression. In support of this hypothesis, we found that insulin increases hepatic expression of SMILE both in vitro and in vivo. However, the identity of the transcription factor that mediates activation of SMILE gene expression by insulin signaling is still elusive and requires further exploration.
One potential candidate transcription factor for mediating insulin signaling is Collectively, we suggest that enhanced expression of SMILE in the fed state is another critical mechanism by which insulin regulates hepatic gluconeogenesis. We have also
shown that activation of AMPK by curcumin, a polyphenol compound, increases SMILE gene expression, which leads to the SMILE-mediated repression of CREBH transcriptional activity via competing with PGC-1α (17) . These data suggest that pharmacological activation of SMILE expression can be utilized as a new therapeutic strategy to relieve hyperglycemia. Genetically altered animal models of SMILE are also needed to fully understand the physiological and pathological role of SMILE in hepatic gluconeogenesis.
Gluconeogenic enzyme gene expression is regulated by both transcription factors and coactivator, such as PGC-1α (8) . In this study, SMILE inhibits HNF4α-or FOXO1-mediated hepatic gluconeogenic genes promoter activity or expression via competing with PGC-1α. In addition, previous report revealed that SMILE inhibits glucocorticoid receptor (GR) which plays an important role in regulation of gluconeogenic genes expression such as PEPCK and G6Pase (16) . Thus, SMILE could (5, 20, 27) . In the immediate early response of insulin, gluconeogenesis is regulated by classical phosphorylation mechanism. Here, we found the role of the delayed effect of insulin on the regulation of gluconeogenesis via induction of co-repressor SMILE.
These results suggest that SMILE has an important role in delayed action of insulin, and the induction of SMILE is another way by which insulin counteracts the action of PGC-1α in the regulation of hepatic glucose metabolism. In this study, we employed the adenoviral approach to explore the regulatory role of SMILE in glucose homeostasis.
Thus, genetically altered animal models of SMILE are also needed to understand the physiological and pathological role of SMILE in hepatic gluconeogenesis.
In fasting condition, PKA/PGC-1α pathway increases hepatic gluconeogenesis. In the fed condition, the PKB/SMILE pathway turns off the PGC-1α-induced hepatic gluconeogenesis via a competitive binding mechanism (Fig. 8) . Overall, our observations provide insight into a novel mechanism for insulin-mediated regulation in hepatic glucose metabolism that can be utilized as a novel therapeutic approach for the treatment of hyperglycemia in diabetes. were injected via the tail-vein into mice (n=5-9). Blood glucose levels measured at day 4 after Ad-US or Ad-shSMILE injection (C). Insulin levels measured at day 4 after Ad-US or Ad-shSMILE injection (D). Q-PCR analysis of gluconeogenic gene expression using total RNA isolated from mouse liver after Ad-US or Ad-shSMILE injection (E).
Mice were injected intraperitoneally with 2 g/kg glucose, 1 g/kg pyruvate or 1 unit/kg of insulin on day 6 after adenoviral injection for glucose tolerance test (F), insulin tolerance test (G) and pyruvate tolerance test (H). Plasma glucose or insulin was measured on blood drawn from the tail vein at designated time points. Error bars show ± s.e.m. n.s., not significant. *P<0.05, **P<0.01, ***P<0.005 by two-tailed Student t-test. 
